ALKemist Bio
Developing Next Generation T Cell Therapies to Provide a New Hope for ALK-positive Cancer Patients
Our Mission
ALKemist Bio’s mission is to change the treatment and prognosis of aggressive ALK+ cancers by developing T cell-based immunotherapies that can eradicate ALK+ cancer cells, overcome resistance and extend remissions for these patients. Leveraging deep collaborations with leading hospitals and research institutions, our objective is to prove the effectiveness of T cell-based therapies to radically extend the gains of ALK inhibition. By closing in on ALK, we aim to bring a sea change to cancer treatment that will mean hope for all patients with ALK+ tumors.
ALK positive tumors
ALK-positive (ALK+) cancer has specific characteristics that unify these tumors regardless of where in the body they occur. ALK+ cancers are highly aggressive and tend to afflict a younger patient population ranging from pediatric indications like neuroblastoma to lung tumors in people who are often non-smokers and younger than 50. ALKemist Bio’s goal is to is improve the treatment of all ALK+ tumors, with an mainly present in patients in the form ofinitial focus on ALK+ non-small cell lung cancer.
​
ALK oncogene
Anaplastic lymphoma kinase (ALK) was originally discovered in 1994, in anaplastic large-cell lymphoma cells. An oncogene is a gene that has the potential to drive the malignant transformation of a normal cell into a cancer cell. Oncogenes are often mutated or re-arranged and expressed at high levels in tumor cells